As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

At least 46 drugs currently in use can cause drug-induced lupus. While lupus-inducing drugs are typically those used to treat chronic diseases, no obvious common denominator links the drugs. That said ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, ...

Symptom control Use of rapidly acting agents tailored to the nature and severity of the manifestation Glucocorticoids: topical for mild cutaneous lupus; low-dose oral for mild disease; moderate to ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

Lupus is often marked by flares, which is when symptoms are usually more obvious.